Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
A single-center, open, single-arm clinical study of the efficacy and safety of a novel
targeted agent in combination with R-ICE in the treatment of relapsed and refractory diffuse
Large B-cell lymphoma.